Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $10.80, but opened at $10.38. Pharming Group shares last traded at $10.46, with a volume of 356 shares traded.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on PHAR. HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer upped their price target on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th.
View Our Latest Stock Report on PHAR
Pharming Group Price Performance
The business has a 50-day simple moving average of $8.95 and a 200 day simple moving average of $8.89. The stock has a market cap of $741.20 million, a P/E ratio of -41.90 and a beta of -0.08. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. On average, analysts forecast that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
